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Abstract 
Background: Prostate cancer is the most common form of non-skin cancer within the United 
States and the second leading cause of cancer deaths. Survival rates for the advanced disease 
remain  relatively  low,  and  conventional  treatments  may  be  accompanied  by  significant  side 
effects. As a result, current research is aimed at alternative or adjuvant treatments that will target 
components of the signal transduction, cell-cycle and apoptosis pathways, to induce cell death 
with little or no toxic side effects to the patient. In this study, we investigated the effect of 
genistein isoflavone, a soy derivative, on expression levels of genes involved in these pathways. 
The mechanism of genistein-induced cell death was also investigated. The chemosensitivity of 
the LNCaP prostate cancer cells to genistein was investigated using ATP and MTS assays, and a 
caspase binding assay was used to determine apoptosis induction. Several molecular targets were 
determined using cDNA microarray and RT-PCR analysis.  
 
Results:  The  overall  data  revealed  that  genistein  induces  cell  death  in  a  time-  and  dose-
dependent manner, and regulates expression levels of several genes involved in carcinogenesis 
and immunity. Several  cell-cycle genes were down-regulated, including the mitotic kinesins, Functional Foods in Heals and Disease: 3:91-105                                                                             Page 92 of 105 
 
cyclins and cyclin-dependent kinases. Various members of the Bcl-2 family of apoptotic proteins 
were  also  affected.    The  DefB1  and  the  HLA  membrane  receptor  genes  involved  in 
immunogenicity were also up-regulated.  
 
Conclusion:  The  results  indicate  that  genistein  inhibits  growth  of  the  hormone-dependent 
prostate cancer cells, LNCaP, via apoptosis induction through regulation of some of the genes 
involved  in  carcinogenesis  of  many  tumors,  and  immunogenicity.  This  study  augments  the 
potential phytotherapeutic and immunotherapeutic significance of genistein isoflavone.  
 
Key  words:  Genistein  isoflavone,  prostate  cancer,  expression  of  genes,  phytotherapeutic 
adjuvant, immunotherapy and chemotherapy 
 
Background  
Prostate cancer is the most common form of non-skin cancer and the second leading cause of 
cancer deaths in the United States [1].  The five year survival rate has increased from 69% to 
99%  over  the  last  25  years  for  the  local  and  regional  disease,  but  has  remained  fairly  low 
(approximately 34%) for the advanced disease
 [1, 2].  Known risk factors include age, race and 
family history, but other factors such as diet and lifestyle, environment and geographic location, 
may also play a role in the progression of this disease [3-6]. New diagnostic tools, improvement 
in  diagnostic  methods  and  increased  testing  for  biologic  markers,  have  contributed  to  early 
diagnosis and better treatment of the early-stage disease
 [7, 8].   
  Current research is aimed at finding new prognostic markers and targets for therapy.  The 
apoptotic and cell cycle pathways provide many avenues for researchers and specific targets for 
cancer therapy. Many research efforts also focus on the effects of dietary phytochemicals. The 
goal of phytochemical research is to identify natural substances that will affect/modulate the 
growth regulatory (signal transduction-, cell-cycle-, growth factor-, and cell death) pathways in 
carcinogenesis. A major phytochemical that has been shown to have chemopreventive properties 
is  genistein  isoflavone.  Genistein  (4,  5,  7-trihydroxyiso-flavone)  is  a  major  isoflavone 
constituent of soy that is found naturally as the glycoside genistin. The latter is hydrolyzed to 
genistein by natural microflora in the intestine. 
 
The molecular structure of genistein 
 
  Genistein is structurally similar to estrogen and therefore possesses the ability to bind to 
estrogenic receptors and regulate cell proliferation [9 -11]. Studies have shown that genistein 
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topoisomerases, microsomal lipid peroxidation, and angiogenesis [10-12].  Genistein has been 
shown to act as an antioxidant and a cell cycle inhibitor, by arresting the cell cycle at the G2/M 
phase [11, 13].  Physiological levels of genistein vary depending on diet consumption, but levels 
ranging from 0.2 to 9.0 µmol have been found [14, 15]. In our study, we focused on using 
genistein levels that might be achieved through use of a supplement or as adjuvant to standard 
therapeutic regimen/treatments such as chemotherapy and/or radiation therapy. 
 
Materials and Methods 
Cell culture 
LNCaP cells were cultured in RPMI-1640 growth medium supplemented with 10% FBS, 1% 
penicillin/streptomycin and L-glutamine.  Cells were incubated for 24-48 hrs at 37
0C and 5% 
CO2 to  achieve 60-80% confluence.  After incubation, the medium was  removed and  either 
replaced with medium alone, as a negative control, or medium containing various concentrations 
of  genistein  (25,  50,  75,  100  µM),  and  incubated  for  24-48  hrs.  Genistein  (4’,  5’,  7-
trihydroisoflavone  (Indofine  Chem.  Co.,  Inc.  Summerville,  NJ,  USA)  was  dissolved  in 
dimethylsulfoxide  (DMSO)  as  a  100  µM  stock  solution  and  diluted  in  RPMI-1640  culture 
medium at a final DMSO concentration of 0.25% (vol/vol); genistein (Gn) concentrations of 0, 
25, 50, 75, 100 µM (Gn0-100) were prepared and stored at -35
oC.  In previous preliminary studies, 
the IC50 for genistein was observed at 25- in PC3 and LNCaP cells. DMSO alone was 
found to be non-toxic to these cells at up to 0.5%. 
 
ATP Assay 
The cytotoxicity of genistein on LNCaP cells was determined using the ATP assay. The assay 
utilizes the D-luciferin substrate which, when oxidized in an ATP-dependent process catalyzed 
by firefly luciferase, generates chemiluminiscence at 560nm. The assay is optimized for fast 
determination  of  low  levels  of  ATP.    Concentrations  down  to  0.1  pmol  can  be  accurately 
determined using the luminescent signal of the luciferase reaction.  
  For determination, cells were plated at a density of 5 x 10
4 cells per well in a 96-well 
plate and incubated for 24 -36 hr to achieve confluence.  After incubation, the cells were treated 
with varying concentrations of genistein, or 1% Triton-X as a positive control. The cells were 
then incubated for 24 hrs under standard conditions.  After incubation, 50 μl of lysis solution was 
immediately added to each well.  After 5 min, 50 μl of solution was transferred from each well of 
the  96-well  plate  to  its  corresponding  well  in  a  white  plate.  Fifty  μl  of  luciferin/luciferase 
solution  was  then  added  to  each  well.    Luminescence  was  determined  after  5  min  using  a 
luminometer.  ATP concentration was determined by comparison of luminescent values against a 
standard curve and % inhibition was calculated. 
MTS Assay 
The MTS assay was also performed to determine the cytotoxicity of genistein towards LNCaP 
cells. This assay utilizes MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-Functional Foods in Heals and Disease: 3:91-105                                                                             Page 94 of 105 
 
sulfophenyl)-2H-tetrazolium, to determine cell viability.  In the presence of viable cells, the 
substrate is reduced to a colored formazan product. In active mitochondria, the tetrazolium ring 
is cleaved in the presence of dehydrogenase enzymes, producing a product that is soluble in 
tissue culture medium. The color intensity is directly proportional to the number of viable cells; 
therefore, relative cell numbers can be determined based on optical absorbance from each well of 
the microtiter plate.  
Briefly, cells were plated at a density of 5 x 10
4 cells per well in a 96-well plate and 
incubated for 24 hrs to achieve confluence.  After incubation, the cells were treated with varying 
concentrations of genistein, or 1% Triton-X as a positive control. After 48hrs incubation, 10 µl 
of MTS reagent was added to each well of the 96-well plate.  The plates were then incubated at 
37
0C and 5% CO2 for 4 hrs and the absorbance was read at 490 nm using a plate reader.  Percent 
inhibition was then calculated.   
 
Apoptosis Induction  
Apoptosis is characterized by morphological changes within the cells, such as, fragmentation of 
nuclear chromatin and cell shrinkage.  These changes can be detected by exposing the cells to 
certain dyes which, when taken up by the cells, cause emission of different fluorescent spectra 
that indicate the level of cell death.  Apoptosis induction was determined using the Vybrant  
 
apoptosis assay kit.  This assay utilizes two dyes, Propidium Iodide (PI) and YO-PRO-1. The 
green fluorescent dye YO-PRO-1 can enter early apoptotic cells, whereas the red fluorescent 
dye PI will only enter dead cells.  Therefore, use of both dyes provides a sensitive indication of 
apoptosis. After staining cells with both dyes, live cells show little or no fluorescence, early 
apoptotic cells will show green fluorescence and dead cells (membrane compromised cells) will 
show both red and green fluorescence.  These can be detected by fluorescence microscopy or 
flow cytometry. 
  Cells were harvested and plated in 6-well plates and incubated for 24 hrs to achieve 
confluence.  After  incubation,  cells  were  treated  with  varying  concentrations  of  genistein,  or 
topotecan (50 µM) as a positive inducer of apoptosis. The cells were then incubated for 48hrs.  
After incubation, cells were harvested and washed with cold phosphate buffered saline (PBS), 
and  cell  density  was  adjusted  to  1x10
6  cells/ml  in  PBS.  1µl  of  YO-PRO-1  stock  solution 
(Component A) was added followed by 1µl of PI stock solution (Component B), to each 1ml of 
cell suspension. The cells were incubated on ice for 20-30 min, then analyzed on the Accuri C6 
flow cytometer
® using 488nm excitation with green fluorescence emission for YO-PRO-1and 
red fluorescence emission for PI.  Data was then analyzed using the CFlow Plus software.  
 
Caspase Protease Analysis 
The  involvement  of  caspase-3  in  the  molecular  pathway  of  genistein-induced  apoptosis  was 
determined by using a caspase-3 colorimetric activity assay.  The assay involves the caspase 
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DEVD-pNA). The p-nitroaniline (pNA) product can be quantified using a spectrophotometer or 
plate reader at 405 nm.  This gives a direct indication of caspase-3 activity.  
  For  caspase-3  determination,  the  cells  were  treated  with  varying  concentrations  of 
genistein or topotecan (50 µM) as a positive inducer of apoptosis.  The cells were counted and 
collected by centrifugation at 1500 rpm for 5 min.  2 x 10
6 cells were then resuspended in 200 µl 
of lysis buffer and incubated on ice for 20 min.  After incubation, the solution was centrifuged 
for 5 min at 10,000 x g and the supernatant was collected.  The BCA protein assay kit (Pierce) 
was used to determine the protein concentration of the samples.  30 µg of protein lysate for each 
sample  was  then  assayed  for  caspase  activity.    Fold-increase  in  caspase-3  activity  was  then 
calculated by  comparing the absorbance values  of the treated samples  to  that of the control 
sample. 
 
cDNA Microarray Analysis 
After treatment of the LNCaP cells with 100 µM genistein, the RNA was extracted using the 
RNeasy  mini  kit  (Qiagen)  according  to  the  manufacturer’s  protocol.    RNA  quality  was 
determined by separation on a 1% agarose  gel and confirmed by spectrophotometry.  Good 
quality RNA was obtained by observing the 18S and 26S bands on the agarose gel, and by using 
absorbance values which gave an A260/280 ratio between 1.8 and 2.  RNA samples were then 
submitted to the Genomics Core of the Scripps Research Institute (Jupiter, FL) for microarray 
analysis.  
  Briefly, RNA samples were quantified using the NanoDrop ND-1000. Double-stranded 
cDNA was prepared from 1 µg of total RNA using the Affymetrix cDNA synthesis kit, and in 
vitro transcribed using an IVT labeling kit (Affymetrix), with the cRNA product purified using a 
GeneChip Sample Cleanup Module (Affymetrix). 20 µg biotin-labeled cRNA was fragmented 
and hybridized to Affymetrix Human Gene chip U133 plus 2.0 array overnight in the Affy 640 
hybridization oven, with a speed of 60 rpm for 16 hr. Microarrays were washed and stained using 
the Affymetrix Fluidics Station FS400.  
 GeneChip arrays were scanned using a GeneChip Scanner 3000 (Affymetrix). The probe 
set intensities were quantified using the GeneChip Operating Software (GCOS) and analyzed 
with  GCRMA  normalization  using  Array  Assist  Software  (Stratagene,  La  Jolla,  CA).  All 
hybridized chips met standard quality control criteria, and mean fluorescence values of each 
array were scaled to a mean intensity of 500. Gene expression of genistein treated cells was 
compared  with  control  (untreated)  cells  to  determine  changes  in  expression  of  target  genes. 
Functional  cluster  analysis  was  done  using  the  Database  for  Annotation,  Visualization  and 
Integrated Discovery (DAVID) 
(16). Results of the microarray analysis were verified by RT-PCR.   
 
RT-PCR Analysis 
The RNA extracted from the cell samples was subjected to RT-PCR analysis using the Access 
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array gene expression changes.  The Access RT-PCR System is designed for convenient and 
sensitive detection and analysis of RNA by one-step RT-PCR.  cDNA synthesis and PCR are 
performed  in  a  single  tube  using  gene  specific  primers  (4µM)  and  1  µg  of  total  RNA  and 
amplified for 35 cycles. The specific primers used were bax, bcl-x, vegf, mdm-2 and beta-actin 
as  an  internal  loading  control.  The  amplified  products  were  separated  on  a  1%  agarose  gel 
stained with ethidium bromide. The results of this experiment were compared to that of the 
microarray analysis to determine if similar changes in gene expression were observed in target 
genes. 
 
Statistical Analysis  
Experiments  were  performed  in  duplicates  to  confirm  similar  results.  Significance  of  the 
differences in mean values was determined using the Student’s t-test and considering P < 0.05 to 
be statistically significant.  
 
Results 
Growth inhibition  
The MTS and ATP assays were done to determine the cytotoxicity of genistein on LNCaP cells.  
The data obtained shows that genistein is able to induce cell death, which is consistent with 
previous studies. The ATP assay showed a steady increase in growth inhibition as genistein 
concentration increased [Figure 1].   
 
 
Figure 1. Determination of cytotoxic effect of genistein on growth inhibition of LNCaP cells,     
using  the  ATP  assay.  Cells  were  treated  with  varying  concentrations  of  genistein  and  % 
inhibition  was  determined using the ATP  assay. Data  are representative of two independent 
experiments and are expressed as the mean ± SEM. Bar =SEM 
 
             Being a more sensitive assay, we were able to see a significant difference after just 24 
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µM  (p  <  0.05).  Above  60  µM,  there  was  a  further  increase  in  inhibition  but  this  was  not 
significant (p > 0.05). 
  The MTS assay also showed a steady increase in inhibition [Figure 2]. At 24 hrs there 
was no significant increase from 25 to 50 µM (p > 0.05). Above 50 µM, there was a significant 
increase in growth inhibition in the cells (p < 0.05). At 48 hrs, there was a significant increase in 
growth inhibition from 0 to 50 µM (p < 0.05), but no significant increase was observed beyond 
that concentration (p > 0.05). At 25 µM, there was no difference between the effect seen at 24 
and  48  hrs,  but  at  higher  concentrations,  the  difference  in  growth  inhibition  observed  was 
significantly  higher  at  48  hrs  (p  <  0.05).  This  provides  further  evidence  that  the  effects  of 
genistein  are  both  time-  and  dose-dependent.  The  EC50  of  genistein  in  LNCaP  cells  was 
determined, from the data obtained, to be about 50-60 µM.   
 
 
 Figure 2. Determination of the cytotoxic effect of genistein on growth inhibition of LNCaP 
cells, using the MTS assay.  Cells were treated with varying concentrations of genistein and % 
inhibition was determined using the MTS assay. Data are representative of two independent 
experiments and are expressed as the mean ± SEM. Bar =SEM 
 
Apoptosis Induction and Caspase-3 induction 
Apoptosis induction in genistein treated cells was investigated and the results show that genistein 
has a dose-dependent effect on LNCaP cells. Flow cytometer analysis of cells stained with the 
fluorescent dyes YO-PRO
®-1 and PI showed an increased level of apoptosis with increasing 
genistein concentration [Figure 3]. This figure shows a comparison of the population of live and 
apoptotic cells that were observed after treatment with genistein. The data show that genistein 
induces apoptosis and inhibits growth of cells, and this response is dose-dependent, as seen with 
the  ATP  and  MTS  assays.  Data  obtained  from  the  caspase-3  assay  indicate  that  caspase-3 
induction increases in a time- and dose-dependent manner. Experiments were performed in the 
presence and absence of a caspase-3 inhibitor and the data show that there was a significant 
difference  in  caspase-3  activity  between  the  two  treatment  groups.  In  the  presence  of  the 
caspase-3  inhibitor,  expression  was  the  same  after  24  hrs,  even  at  high  concentrations  of Functional Foods in Heals and Disease: 3:91-105                                                                             Page 98 of 105 
 
genistein (Figure 4). However, in the absence of any inhibition there was a 1.5-fold increase at 
50 µM after just 24 hrs, and almost a 5-fold increase at the same concentration, after 48 hrs (data 
not shown). These results correlate with the data obtained in the apoptosis assay, and indicate 
that genistein-induced cell death involves the activation of the caspase pathway.    
 
 
 
Figure  3.  Bar  chart  showing  distribution  of  viable  and  apoptotic  cells  with  respect  to    
concentration  of  genistein.    Cells  were  treated  with  varying  concentrations  of  genistein  and 
analyzed by flow cytometry, using YO-PRO
®-1 and PI stains to detect apoptosis induction. Data 
is representative of two independent experiments.  
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Figure 4. Effect of genistein treatment on caspase-3 activity in LNCaP cells after 24 hrs.  Cells 
were treated and changes in caspase-3 activity were determined. Data is representative of  two 
independent experiments.  
 
Microarray Analysis 
The effect of genistein on gene expression in LNCaP cells was investigated using microarray 
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of  genes  in  genistein  treated  and  untreated  LNCaP  cells.  A  2-fold  difference  in  expression, 
compared to the control, was considered significant. A functional annotation cluster analysis of 
all these genes was performed, and changes in specific pathways were investigated based on 
KEGG  annotations  [17].  A  number  of  pathways  were  found  to  be  affected  by  genistein 
treatment. The cell cycle pathway was the most affected, with 51 genes being down-regulated 
(data not shown). The p53 signaling pathway was also affected with 14 genes being up-regulated 
and 14 being down-regulated.   
The main cell cycle genes affected included the kinesins, cyclins and cyclin-dependent 
kinases that are involved in regulation of the cell cycle (Table 1).  
 
Table 1. Cell cycle genes showing genistein-induced differential expression  
Down regulated genes 
   Cyclins B1, B2, E1, E2, F 
   Cdks 2, 3, 4, 5 
   Tp53 (Li Fraumeni syndrome) 
   TGFB2 
   Tfdp1 
Up regulated genes 
   Mdm2 
  TP53AP1 
  TP53INP2 
  CDKN1A 
  CDKN2B   
 
Other  genes  that  were  down-regulated  include  TGFB2,  and  TP53  Li  Fraumeni  (the 
mutated form of the p53 gene), which are known to be involved in tumor progression. Up -
regulated genes include p53 related proteins, mdm-2 and cdk inhibitors 1a and 2b (Table 1). A 
number of apoptosis related genes were affected as  well (Table 2), including members of the 
Bcl-2 family.   
 
Table 2. Apoptosis-related genes showing genistein-induced differential expression  
Down regulated genes 
   Bcl-2, Bcl-x, BCLAF-1,          
   BCL11A 
   NFκB1 
   FAIM2 
   MAP2K5 
Up regulated genes 
  Fas 
  TNFSF9 
  BIRC3 
  BAM (BIM/Bcl2L11) 
 
Bcl-2 and Bcl-x, which are anti-apoptotic members, were found to be down-regulated 
following  genistein  treatment,  and  Bam,  which  is  an  apoptosis  inducer,  was  found  to  up-
regulated. Genistein was found to have no effect on Bax, maspin, and VEGF expression levels. Functional Foods in Heals and Disease: 3:91-105                                                                             Page 100 of 105 
 
Other genes that were affected include members of the TNF superfamily, which are involved in 
the apoptotic pathway. In addition, the DefB1 and the HLA membrane receptor genes involved 
in immunogenicity were also up-regulated.  
Down-regulated  genes  showing  a  20-fold  or  higher  expression  were  further  analyzed 
using the DAVID annotation tool and a functional annotation cluster was performed. The results 
revealed three gene clusters containing genes with similar functions (Table 3).  
 
Table 3. Functional cluster analysis of genes showing decreased expression of 20-fold or less    
 and increased expression of 10-fold or more 
 
Down regulated genes 
Cluster 1 
   KIF2C, KIF4A, KIF14, KIF15, KIF20, KIF23 
   BUB1, PLK1, PLK4, CENPO, CENPF 
   ESPL1, DLG7, TTK, NEK2, SPC25 
 
Cluster 2 
    MCM10, NEIL3, ST18 
 
Cluster 3 
   E2F2, E2F8 
Up regulated genes 
   NEU1 (sialidase1), CD68, Insig1, GPNMB 
 
Group 1 had 24 genes including the kinesins and a number of other cell-cycle related 
genes. Groups 2 and 3 both had 3 genes; the other 38 genes were omitted from the cluster by the 
program. In group 1, the kinesins were significantly affected showing fold-changes ranging from 
22  to  87.  The  second  group  included  the  MCM10  gene,  which  interacts  with  the  origin  of 
recognition complex (ORC) and two other regulatory proteins, CDC6 and CDT1, in formation of 
the pre-replication complex.  The third group contained genes that code for the transcription 
factors, E2F2 and E2F8, which are involved in transcription of cell cycle related genes.  
Up-regulated genes having a 10-fold or higher differential change in expression levels 
were also analyzed further, and clustered according to function. Only one functionally similar 
group of genes was found which included CD68, GPNMB and NEU1, which seem to play a role 
in immune cell recognition of the cancer cells. BrunoL6 gene was not included in the cluster, but 
this gene was the most up-regulated gene, showing a fold-change of 116.0.  
 
RT-PCR Analysis 
A few  genes were selected and subjected to  RT-PCR analysis to  confirm  the results  of the 
microarray. The selected genes include Bax, Bcl-x, Mdm-2, VEGF and β-actin (which was used 
as a loading control). The results indicate that Mdm-2 showed an increase in expression when 
cells were treated with genistein; which correlates with the microarray results. VEGF and Bax 
expressions showed no significant changes after genistein treatment; which also correlates with 
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PCR and microarray analysis. These findings indicate that the PCR results are consistent with the 
microarray data obtained, and confirm the effects of genistein on gene expression within the 
prostate cancer cells.     
 
Discussion 
Growth Inhibition of LNCaP Cells 
Genistein has been shown to induce cell death in cancer cells through apoptosis; and previous 
studies have indicated that this is a time- and dose-dependent effect [18-20].  The results of the 
ATP  and  MTS  proliferation  assays  are  consistent  with  these  studies  and  indicate  the 
chemosensitivity of LNCaP prostate cancer cells towards genistein. Based on our results, the 
EC50 of genistein was found to be between 50 and 60 µM, which is also consistent with the 
results of previous studies [20]. Therefore, our study used a concentration range close to the EC50 
value that was found in our preliminary studies.  
  These concentrations are above the physiological values observed in persons that have a 
high soy diet. For our studies, we wanted to look at the efficacy of concentrations that may be 
present in persons taking a genistein supplement or using it as an adjuvant drug.  
Apoptosis and caspase-3 induction  
The results of the apoptosis and caspase-3 assays revealed that genistein can induce apoptosis 
and increase caspase-3 activity within the cells, as shown previously [21, 22]. Genistein’s effect 
on apoptosis in the LNCaP cells was found to be dose-dependent, as observed from the results of 
the flow cytometry experiment.  Cells  in  early  apoptosis  were detected as  low  as  25 µM  of 
genistein treatment and this percentage increased with the concentration of genistein.  
Caspase-3 activity was also increased after exposure to genistein. Caspase-3 is an effector 
caspase and plays a central role in apoptotic cell death, so detection of this caspase indicates 
activity  of  other  up-stream  caspases.  Once  activated,  caspase-3  has  been  shown  to  initiate 
fragmentation of DNA which ultimately leads to cell death [22].  
The  microarray  analysis  revealed  that  there  was  no  change  in  expression  levels  of 
caspases. Since caspases are synthesized and found in the cell as inactive proteins, this could 
indicate that genistein increases activity of the protein but has no effect on gene expression 
levels. 
 
Gene Expression Profiles 
The microarray results revealed that a number of genes were affected/regulated by genistein. 
Several  major  pathways  were  shown  to  be  affected  including:  the  cell-cycle  pathway,  p53 
signaling  pathway,  and  apoptosis  pathways.  From  previous  studies,  we  know  that  genistein 
affects gene expression, even at low concentrations. One study found that at physiologically 
achievable  concentrations  of  genistein  (<  10  µM),  some  pathways  were  affected,  but  other 
pathways, such as the cell-cycle, DNA damage and stress response pathways, needed higher 
concentrations  to  elicit  a  significant  response;  in  conformity  with  the  present  results  [23]. Functional Foods in Heals and Disease: 3:91-105                                                                             Page 102 of 105 
 
Another study showed that at very high genistein concentrations (100 µM), not more than four 
genes  were down-regulated,  and only seven  genes  were up-regulated by more than a 2-fold 
change in expression [24]. This suggests that finding the EC50, and using concentrations close to 
that value will have more of an effect on cancer cells, while still being less toxic to normal cells, 
as observed in this study.  
 
Down-regulation of Genes by Genistein 
The majority of down-regulated genes were found to be involved in the cell-cycle, suggesting 
that  the  major  mechanism  of  treatment-induced  cell  death  involves  regulation  of  genes  that 
control the cell-cycle. If cell-cycle genes are down-regulated, this will halt progression of the 
cell-cycle, leading to apoptosis within the cell.  In the present study, the main group of cell cycle 
genes affected was comprised of kinesins. Kinesins are a large super-family of motor proteins 
that  are  involved  in  a  wide  range  of  cellular  processes  such  as  mitosis,  meiosis  and  cargo 
transport. Our data showed that mostly the mitotic kinesins were affected. This further indicates 
the mechanistic specificity of genistein treatment.  
Our data revealed that cyclin A2 was the most down-regulated gene (25.9- fold change) 
from  this  family.  The  G2/M  checkpoint  is  controlled  by  interaction  of  cyclin  A/cdk2,  and 
silencing of this gene was found to delay entry into mitosis [25], while over-expression was 
associated with poor prognosis in breast cancer patients [26]. Cyclin B1 and B2 were also down-
regulated, which, according to a study investigating the correlation between cyclin B levels and 
cell-cycle progression, co-depletion of both cyclins can result in mitotic arrest within the cells 
[27].  
The  anti-apoptotic  proteins  Bcl-2  and  Bcl-x  were  down-regulated  and  Bim  was  up-
regulated by genistein. A decrease in Bcl-x expression was observed using both microarray and 
PCR analysis. Cell survival depends on a proper balance of these proteins; therefore, effective 
agents can be described as those that shift the balance in favor of apoptosis [28]. As seen from 
our results, genistein-induced cell death is aided by an increase in expression of pro-apoptotic 
member, Bim and a decrease in expression of anti-apoptotic members, Bcl-x and Bcl-2. Gene 
expression  of  Bax  showed  no  significant  change  following  genistein  treatment  (which  was 
confirmed by PCR analysis), although protein levels were increased (results not shown). This 
suggests possible involvement of genistein in post-translational activation of Bax. 
MMPs and VEGF play a major role in cancer metastasis and previous studies correlated 
genistein treatment with decreased protein activity [29, 30]. Presently however, the microarray 
and  PCR  analysis  revealed  no  significant  changes  in  gene  expression  levels  following  the 
treatment, which may indicate involvement of genistein in post-translational activation of these 
genes.   
Up-regulation of Genes by Genistein 
Bruno-L6 was the most up-regulated gene, showing a fold-change of 116.0. This gene plays a 
role  in  mRNA  processing  and  alternative  splicing,  and  belongs  to  a  family  of  proteins  that Functional Foods in Heals and Disease: 3:91-105                                                                             Page 103 of 105 
 
regulate mRNA stability and translation [31]. A study of the Xenopus homolog of this gene 
revealed that it mediates sequence specific deadenylation and repression of Eg5 (Kinesin5) [32], 
indicating that up-regulation of this gene by genistein may play a role in the down-regulation of 
kinesins. TP53INP1, TP53INP2 and TP53AP1 were also found to be up-regulated by genistein. 
TP53INP1 regulates p53 activity and is expressed during cellular stress to induce apoptosis [33]. 
TP53AP1 is a p53 target protein that also functions in response to cellular damage [34].  
In our study, Mdm-2, which inhibits p53 activity, was also up-regulated by genistein 
(3.7-  fold  changes).  This  expression  change  was  confirmed  using  PCR  analysis.  Increased 
expression of Mdm-2 was unexpected and may explain why an increase in the expression levels 
of  these  p53-associated  proteins  was  not  observed.  Without  increased  Mdm-2  expression,  a 
greater effect on apoptotic induction may have been apparent.  
 
Conclusion 
Our study provides evidence that genistein affects expression of genes that are involved in  
carcinogenesis. These results imply that genistein as a phytotherapeutic adjuvant may augment 
standard immunotherapy and chemotherapy, help to reduce toxic side-effects, and increase the 
patient’s response to therapy. A number of other molecular targets were also identified, and 
further  research  will  enable  us  to  elucidate  the  significance  of  these  genes  and  further 
mechanisms of genistein-induced apoptosis in prostate cancer cells.  
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